olivLaw · US equity research
Bonk, Inc. BNKK
Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844 · Vertical: Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844)
Bonk, Inc. (BNKK), formerly Safety Shot, has moved from the Sure Shot dietary supplement, which aimed to support alcohol metabolism, toward digital assets tied to the BONK ecosystem. The shift, along with large net losses and a reverse stock split, makes the company a profile worth watching closely.
At the close of 04 Nov 2026, Bonk, Inc. (BNKK) stock was 1.16 USD (+6.42% on the day), with market capitalisation 9.3 m USD, beta 1.36, 52-week range 0.91–7.88 USD. Latest reported quarter (Q2 2026): revenue of 792.9 k USD (+1,664.1% YoY), net income of -6.1 m USD (−145.3% YoY), diluted EPS -0.76 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 45.1
- neutral
- Bollinger (20, 2)
- 0.97 – 1.41
- in the lower half of the band · %B 0.43 · band width 36.5%
- SMA 50 / 200
- 1.35 / 2.13
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.08 / -0.08
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −24.2% | −1.1% | −23.1 pp | — |
| 3 months | +10.5% | −0.5% | +10.9 pp | — |
| 6 months | −56.9% | +4.4% | −61.3 pp | — |
| Year to date | −55.0% | +12.3% | −67.4 pp | — |
| 1 year | −82.0% | +13.5% | −95.5 pp | +9.7% |
| 3 years | −97.8% | +76.4% | −174.2 pp | −12.3% |
| 5 years | −98.2% | +63.7% | −161.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 110.2 k | 182.2 k | 42.1 k | 44.9 k | 1.5 m | 515.4 k | 786.3 k | 792.9 k |
| Cost of revenue | 402.4 k | 598.6 k | 21.1 k | 21.1 k | 1.5 m | 1.2 m | 744.0 k | 772.4 k |
| Gross profit | -292.2 k | -416.5 k | 21.0 k | 23.9 k | 543.1 k | 650.1 k | 3.6 m | 391.1 k |
| Research & development | 10.3 k | -171.1 k | 9.0 k | 6.5 k | 8.7 k | 0 | 300 | 0 ≈ |
| Depreciation & amortisation | 109.0 k ≈ | 110.8 k | 110.8 k | 110.9 k ≈ | 202.2 k ≈ | 230.6 k | 209.2 k | 164.5 k ≈ |
| Interest expense | 8.2 k ≈ | 7.2 k | 91.9 k | 115.4 k | 132.5 k | — | — | — |
| Net income | -11.9 m | -13.5 m | -5.3 m | 13.4 m | -33.6 m | -42.7 m | -1.8 m | -6.1 m |
| Diluted EPS | -0.21 | — | -0.08 | 3.12 | -0.22 | — | -0.23 | -0.76 |
| Operating cash flow | — | — | -4.6 m | -728.9 k ≈ | — | — | -1.9 m | -2.2 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | ⚠ 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.5 k | 1.1 m | 2.9 m | 120.6 k | 202.7 k | 702.0 k | 2.1 m |
| Revenue YoY | unavailable | +16,409.1% | +169.9% | — | +68.0% | +246.4% | +201.6% |
| Net income | -925.5 k | -6.3 m | -28.1 m | -15.2 m | -15.1 m | -49.4 m | -68.2 m |
| Net income YoY | unavailable | unavailable | unavailable | — | unavailable | unavailable | unavailable |
| Diluted EPS | -0.15 | -0.86 | -1.69 | -0.69 | -0.49 | -31.77 | -17.02 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | — | unavailable | unavailable | unavailable |
| net % | -14,337.1% | -590.2% | -977.0% | -12,619.9% | -7,442.2% | -7,038.7% | -3,220.4% |
| Free cash flow | unavailable | -2.8 m | -7.7 m | -6.4 m | unavailable | unavailable | unavailable |
The series breaks before 2022: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- unavailable USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 35.0 m USD
- Total assets
- 41.0 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.01x
- ROE
- unavailable
- ROA
- -282.3%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.1 m | 2.9 m | 120.6 k | 202.7 k | 702.0 k | 2.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Cost of revenue | 624.6 k | 2.3 m | 325.2 k | 277.1 k | 3.1 m | 2.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Gross profit | 441.1 k | 535.5 k | -204.5 k | -74.5 k | -2.4 m | 1.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Research & development | 308.4 k | 1.1 m | 1.6 m | 100.6 k | 100.6 k | 24.2 k | SEC (XBRL)· 31 Mar 2026verified |
| Depreciation & amortisation | 161.4 k | 187.9 k | 20.6 k | 214.1 k | 428.8 k | 654.4 k | SEC (XBRL)· 31 Mar 2026verified |
| Interest expense | 116.8 k | 1.7 m | 60.6 k | 49.0 k | 34.7 k | — | SEC (XBRL)· 28 Mar 2025verified |
| Net income | -6.3 m | -28.1 m | -15.2 m | -15.1 m | -49.4 m | -68.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Diluted EPS | -0.86 | -1.69 | -0.69 | -0.49 | -31.77 | -17.02 | SEC (XBRL)· 31 Mar 2026verified |
| Weighted average diluted shares | 7.3 m | 16.6 m | 22.1 m | 30.9 m | 1.6 m | 4.0 m | SEC (XBRL)· 31 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 4.3 m | 11.8 m | — | — | — | — | SEC (XBRL)· 16 May 2022verified |
| Receivables | — | 695.3 k | 26.4 k | 5.6 k | 283.6 k | 90.1 k | SEC (XBRL)· 31 Mar 2026verified |
| Inventories | 225.9 k | 304.3 k | 151.2 k | 795.8 k | 233.5 k | 949.3 k | SEC (XBRL)· 31 Mar 2026verified |
| Current assets | 5.0 m | 16.3 m | 6.8 m | 7.7 m | 2.6 m | 6.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Property, plant & equipment, net | 35.6 k | 109.1 k | 52.5 k | 28.3 k | 94.0 k | 66.2 k | SEC (XBRL)· 31 Mar 2026verified |
| Goodwill | 941.9 k | 941.9 k | 0 | 0 | 0 | 14.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Intangibles (excl. goodwill) | 559.8 k | 364.4 k | 291.5 k | 4.5 m | 4.4 m | 1.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Total assets | 6.5 m | 18.9 m | 8.7 m | 12.7 m | 7.3 m | 41.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Accounts payable | 688.8 k | 1.2 m | 1.5 m | 1.5 m | 2.2 m | 2.5 m | SEC (XBRL)· 31 Mar 2026verified |
| Current liabilities | 2.1 m | 1.6 m | 4.5 m | 3.6 m | 9.4 m | 6.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Total liabilities | 2.1 m | 2.3 m | 5.0 m | 3.9 m | 9.5 m | 6.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Equity | 4.4 m † | 16.6 m † | 3.7 m † | 8.8 m † | -2.2 m † | 35.0 m † | SEC (XBRL)· 31 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.7 m | -7.6 m | -6.4 m | — | — | — | SEC (XBRL)· 03 Apr 2023verified |
| Capex | 44.0 k | 88.3 k | 15.0 k | 106.2 k | 87.2 k | — | SEC (XBRL)· 28 Mar 2025verified |
| Free cash flow | -2.8 m ≈ | -7.7 m ≈ | -6.4 m ≈ | — | — | — | SEC (XBRL)· 03 Apr 2023derived |
| Investing cash flow | -246.0 k | -13.1 m | -2.5 m | -330.0 k | -4.9 k | 5.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Financing cash flow | 6.7 m | 28.2 m | -904.2 k | 12.8 m | 15.6 m | 21.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Share repurchases | — | — | 2.9 m | — | — | — | SEC (XBRL)· 01 Apr 2024verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 9.3 m USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -2,330.4% | 7 (vs peers) | 33% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 159.9% | 100 (on a fixed band) | 44% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.0x | 21 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial21/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial7/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
BONK, INC. (BNKK). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 2.1 m USD in 2025; YoY growth 201.6%; net margin -2,330.4%; ROE -332.4%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 159.9%
What contradicts it
- Net margin: -2,330.4%
- Current ratio: 1.0x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| CLColgate-Palmolive Company | 78.5 bn | 38.7 | 358.9% | 9.6% | +1.4% | +23% / +25% |
| KVUEKenvue Inc. | 37.1 bn | 21.9 | 16.3% | 10.9% | −2.1% | +34% / +4% |
| ELFe.l.f. Beauty, Inc. | 6.7 bn | 113.6 | 6.0% | 3.4% | +24.6% | +49% / −4% |
| IPARInterparfums, Inc. | 4.0 bn | 23.3 | 19.5% | 11.3% | +2.5% | +52% / −1% |
| COTYCoty Inc. | 3.1 bn | — | -18.5% | -10.4% | −1.5% | +5% / −70% |
| EPCEdgewell Personal Care Company | 1.4 bn | — | -6.2% | -4.2% | −1.3% | +66% / −15% |
| SLSNSolesence, Inc. | 64.6 m | — | -15.1% | -3.8% | +18.6% | −60% / +22% |
| AXILAxil Brands, Inc. | 38.2 m | 16.7 | 23.3% | 9.3% | +17.5% | +10% / unavailable |
| UGUnited-Guardian, Inc. | 31.5 m | 12.8 | 21.4% | 22.0% | −13.4% | +18% / −16% |
| CABRCaring Brands, Inc. | 9.3 m | — | -3,889.1% | -183,298.7% | unavailable | −13% / unavailable |
| BNKKBonk, Inc. | 9.3 m | — | -332.4% | -2,330.4% | +201.6% | −82% / −98% |
| YCBDcbdMD, Inc. | 4.5 m | — | -40.3% | -13.8% | −1.5% | −34% / −93% |
| ELEstee Lauder Companies Inc | — | 111.7 | 9.3% | 2.4% | +5.0% | +19% / −12% |
| ODDOddity Tech Ltd | — | 12.0 | 32.6% | 13.7% | +25.2% | −50% / −37% |
| HLNHaleon plc | — | — | 10.2% | 15.1% | −1.8% | −6% / +8% |
| YSGYatsen Holding Limited | — | — | -2.7% | -1.9% | +32.2% | −67% / −49% |
1- and 3-year price returns: for BNKK from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Bonk, Inc. (BNKK), formerly Safety Shot, has moved from the Sure Shot dietary supplement, which aimed to support alcohol metabolism, toward digital assets tied to the BONK ecosystem. The shift, along with large net losses and a reverse stock split, makes the company a profile worth watching closely.
SWOT
Strengths
- The company holds a product with GRAS-category ingredients and a clinical study that showed a statistically significant reduction in blood alcohol content 2. The Yerbaé acquisition added a product line and distribution channels.
- The company's shares are listed on Nasdaq, and the reverse split has changed the structure of shares outstanding 1.
- The digital strategy gives an early position in a growing sector, and partnerships with the BONK project could bring visibility.
Weaknesses
- Net losses are large relative to revenues, and the supplement business did not generate positive cash flow last year 1.
- The company employs a small number of its own staff, which limits its capacity to execute across several business lines 2.
- The BONK token strategy has not been tested over an extended period or under different market conditions, which makes outcomes hard to predict 1.
Opportunities
Threats
- The volatility of the BONK token could quickly reduce the value of the company's assets and affect the share price 1.
- Regulatory changes or enforcement actions against crypto platforms could limit access to tokens 1.
- Strong competition in beverages and supplements could pressure margins and sales of traditional products.
Risks
- Volatility of the BONK tokenhigh
A decline in the BONK token price could materially affect the company's results and the value of its shares 1.
- Large net losseshigh
The company reported major net losses in recent years, and the supplement business did not generate enough cash to cover its obligations 1.
- Dependence on external financinghigh
If equity or debt financing is not available on favorable terms, the strategy could be put at risk 1.
- Regulatory uncertaintymedium
New rules for digital assets could affect the token's value and the company's ability to hold or transfer such assets 1.
- Management changesmedium
Recent departures of officers and board members could disrupt continuity of management 1.
Investment thesis
What would need to be true (bull case)
- If the BONK token and its ecosystem grow in adoption, the company's digital assets could become a meaningful part of its value 1.
- The Yerbaé acquisition and the Sure Shot product could support a revenue base in functional beverages if sales expand 12.
- If digital asset regulation becomes clearer, the company could benefit from a more predictable market for these assets 1.
What would break the thesis
- Token volatility and large losses could make performance hard to sustain without operating gains 1.
- Dependence on external financing could limit the company's flexibility if markets become more restrictive 1.
- The shift from beverages to digital assets could reduce the core business before the new strategy has been sufficiently tested 1.
What to watch
- Trend in the BONK token price and its impact on the value of digital assetsQ3 2026
- Revenues and margins from Yerbaé and Sure ShotQ3 2026
- Any regulatory changes for digital assets that could affect the strategy2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The company was formerly known as Jupiter Wellness and built its activity on health and wellness products, including the Sure Shot supplement, launched in December 2023 on its own website, on Amazon and in several big box stores 1. In June 2025 it completed the acquisition of Yerbaé, a premium plant-based energy beverage company, to expand in functional beverages 1. From September 2025 the focus shifted toward digital assets and decentralized finance, notably the BONK project, which has already drawn a share of management attention 1. Sure Shot is sold with 28 active ingredients, all in the GRAS category 2.
Segments
Dietary supplements (Sure Shot)
The core product, a 4-ounce liquid supplement with 28 active ingredients, sold online and in retail, for which the company reported a clinical study with 36 participants 2. Sure Shot remains the main active product, and the company intends to launch a stick pack version 2.
Energy beverages (Yerbaé)
The Yerbaé acquisition brought premium plant-based energy drinks distributed through retail and e-commerce and expanded the company's presence in functional beverages 1. The role of this segment in the strategy appears to have diminished as the focus moved to digital assets 1.
BONK digital assets
Since September 2025 the company has held BONK tokens received in a transaction with a Solana-based project, which it accounts for as indefinite-lived intangible assets 1. The value of these assets is remeasured each period and decreases are recognized in earnings, so results depend on the token's price 1.
Market context
The company operates in the US dietary supplement and functional beverage market, where products are sold through Amazon, retail and its own websites 1. In parallel, digital assets tied to the BONK ecosystem create exposure to crypto markets, where volatility is high, and the company acknowledges that the value of the BONK token could decrease substantially 1.
Trends
- Volatility of the BONK tokenheadwind
The company describes the BONK token as a highly volatile asset whose price decline could affect financial results and the market price of its securities 1. This factor could become a pressure if crypto markets deteriorate.
- Regulation of digital assetsmixed
The legal framework for digital assets remains uncertain in the US and other countries, and new rules could change the token's value or the company's ability to hold and transact it 1. Regulatory clarity could support the sector, but new restrictions could complicate the strategy.
- Shift from beverages to digital assetsmixed
The company has redirected its strategy from beverage sales toward digital assets and decentralized finance, a change that could reduce dependence on traditional products but adds new risks 1. The effect depends on its ability to fund operations from other sources.
- Dependence on external financingheadwind
To meet its obligations the company relies on equity or debt financing, and access to these sources could become harder if token values fall 1. Funding pressure remains an important factor.
Competitive position
The company acknowledges that the health and wellness market, including beverages, includes many companies 1. In digital assets, competition comes from other crypto assets offering better speed, security or government backing 1.
- Other energy and wellness beverage makers
Competitors in functional beverages, referred to generically by the company without naming them in the source.
- Other crypto assets offering better speed or security
Competing digital assets are mentioned in the BONK token risk factors without specific entities being named.
- Crypto trading platforms
Exchanges and trading platforms are affected by regulation and can influence access to tokens.
- Other dietary supplement producers
Supplement companies compete for the same sales channels and consumers.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Proxy statement29 Oct 2026
- Current report11 Sept 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Quarterly report13 May 2026
- Current report30 Apr 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report28 Apr 2026Departure or appointment of officers
- Annual report31 Mar 2026
- Current report14 Jan 2026Departure or appointment of officers
- Current report05 Jan 2026Departure or appointment of officers
- Current report29 Dec 2025Shareholder vote
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Bonk, Inc. · 31 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Bonk, Inc. · 14 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.